Paclitaxel-based chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy failure: A case series of 5 patients

Hisato Igarashi, Tetsuhide Ito, Terumasa Hisano, Nao Fujimori, Yusuke Niina, Mikihiko Yasuda, Toyoma Kaku, Susumu Matsuo, Takamasa Oono, Masahiro Yoshinaga, Hiroyuki Sakai, Ryoichi Takayanagi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background/Objectives: Gemcitabine (GEM) is a gold-standard chemotherapy agent for advanced pancreatic cancer. Because of the malignant character of the disease, nearly all patients show disease progression despite treatment with GEM-based chemotherapy; therefore, second-line chemotherapy may be beneficial for these patients. We report a retrospective analysis of 5 patients with advanced pancreatic cancer, treated with a paclitaxel-containing regimen as second-, third- or fourth-line chemotherapy after various therapies, such as a GEM-based regimen, S-1 regimen, and chemoradiation. We retrospectively analyzed the efficacy and adverse events, and evaluated the paclitaxel-containing regimens. A review of the literature is also discussed. Results: The median overall survival from the start of salvage therapy was 10.7 months. The disease control rate of the paclitaxel-containing regimen according to RECIST criteria was 60%, including complete response in 0 patients, partial response in 3, and stable disease in 2. Two patients had malignant ascites at the start of this salvage therapy, and in both of them the ascites and clinical complaints improved. Grade 3 and 4 hematological adverse events were observed in 2 patients and 1 patient, respectively. Conclusion: Salvage paclitaxel-based therapy could be beneficial to advanced pancreatic cancer patients who maintain good performance status after several chemotherapy failures.

Original languageEnglish
Pages (from-to)534-541
Number of pages8
JournalCase Reports in Oncology
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 1 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this